Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
Explore this paper's citation graph
Summary
It is concluded that the combination of direct enhancement of Teff cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti–CTLA- 4 antibodies during cancer immunotherapy.
- Type
- article
- Published
- 2009-08-03
- Cited by
- 937
- References
- 33
- Access
- Open access
- OpenAlex
- https://openalex.org/W2013043293
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2743422
Keywords
CTLA-4, Blockade, Cytotoxic T cell, T cell, Cancer immunotherapy
References
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.
- Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
- Secondary but not primary T cell responses are enhanced in CTLA‐4‐deficient CD8+ T cells
- CTLA-4 regulates induction of anergy in vivo.
- ICER/CREM‐mediated transcriptional attenuation of IL‐2 and its role in suppression by regulatory T cells
- An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells.
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
- CTLA‐4 regulates cell cycle progression during a primary immune response
- Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses.
- Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.
- B7-1 or B7-2 Is Required to Produce the Lymphoproliferative Phenotype in Mice Lacking Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4)
- Normal pathogen‐specific immune responses mounted by CTLA‐4‐deficient T cells: a paradigm reconsidered
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Complement C4 Inhibits Systemic Autoimmunity through a Mechanism Independent of Complement Receptors Cr1 and Cr2
- Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
- Molecular interactions mediating T cell antigen recognition.
Cited by
- The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting
- Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy
- Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
- Biology and clinical observations of regulatory T cells in cancer immunology.
- Immunotherapy for Lung Cancer
- The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.
- The Safety of Available Immunotherapy for the Treatment of Glioblastoma
- Cancer immunotherapy targeting T cell costimulatory molecules
- FcγRIIB as a key determinant of agonistic antibody efficacy.
- New Approaches in Immunotherapy for the Treatment of Lung Cancer.
- The role of inflammation in kidney cancer.
- Terapias combinadas contra tumores murinos: inmunoterapia y quimioterapia. Relación de la eficacia del tratamiento con el estado inmunológico del portador
- T-Cell Mediated Mechanisms of Autoimmunity, Anti-Tumor Immunity and Tumorigenesis
- CD28 costimulation in T cells : requirements, outcomes and regulation
- Biodegradable microparticles for in situ immunization against cancer
- Tumor macrophages protective and pathogenic roles in cancer development.
- Indoleamine 2,3-dioxygenase confers resistance to chemotherapy and γ radiation to cancer cells, independent of direct immune involvement
- Genomic Analysis of Infectious Agents, Mutations and Immune Cells Associated with Cancer
- Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies
- Immune regulation by dendritic cells and T cells--basic science, diagnostic, and clinical application.
Related papers
- Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer
- A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade.
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
- Tumor organoid-originated biomarkers predict immune response to PD-1 blockade.
- A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report
- Loss of E-cadherin inhibits CD103 anti-tumor activity and reduces checkpoint blockade responsiveness in melanoma
- Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy In Need of Further Investigation
- Research advances in radiotherapy combined with immune checkpoint blockade
- Immune checkpoint blockade in CNS tumors
- Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer